Journals / Türk Hematoloji Onkoloji Dergisi / 2004 / Cilt: 14 - Sayı: 3

Prognostic factors in breast cancer patients treated with adjuvant chemotherapy

Adjuvant kemoterapi uygulanmış meme kanserli hastalarda prognostik faktörler

Pages
123–127
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Other factors were not found to be statistically important on prognosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Breast cancer is an important health problem.
📊
Key Findings & Data:The most important prognostic and predictive factors are axillary lymph node involvement, tumor size, hormone receptor status, c-erbB-2 and p53 expression.
💡
Conclusion & Impact:Other factors were not found to be statistically important on prognosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Breast cancer is an important health problem. Many prognostic and predictive factors are being intensively investigated to determine most appropriate treatment option for patients with breast cancer. The most important prognostic and predictive factors are axillary lymph node involvement, tumor size, hormone receptor status, c-erbB-2 and p53 expression. In this study, we have investigated impact of these prognostic factors on patient survival in patients with breast cancer who have received adjuvant AC (adriamycin, cyclophosphamide) chemotherapy. Median follow up time was 48 months. In this period, 5 patients had metastases. By Kaplan-Meier method, we have found that disease-free survival at two years was %97, at four years was %73.1. Median disease-free survival was 42.2 months. By log-rank method, we have found that p53 has negative impact on prognosis. This finding is compatible with current literature. Other factors were not found to be statistically important on prognosis.

Özet

Meme kanseri önemli bir sağlık sorunu haline gelmiştir. Tedavi seçeneklerini en uygun şekilde kullanmak için bir çok prognostik ve prediktif faktör üzerinde yoğun olarak çalışılmaktadır. Bunlardan en önemlileri aksiller lenf nodu tutulumu, tümör çapı, hormon reseptör pozitifliği, p53 ve C-erbB2 onkoprotein varlığıdır. Biz çalışmamızda bu prognostik faktörlerin, opere meme kanseri tanısı ile adjuvant AC (Adriamisin-siklofosfamid) kemoterapisi almış hastalarımızda etkilerini araştırdık. Hastalar ortalama dört yıl süreyle takip edildi. İzlem süresinde 40 hastadan 5'inde metastaz tespit edildi. Kaplan-Meier yöntemi ile hastalıksız sağ kalım 2 yıl için %97.5, 4 yıl içinse %73.1 olarak hesaplandı. Hastalıksız sağ kalım ortalama 42.2 aydı. Log-rank ile yapılan subgrup sağ kalım anazlizinde ise p53 varlığının prognozu kötü yönde etkilediği tespit edildi. Diğer faktörlerin ise prognoz üzerine istatistiksel olarak anlamlı etkide bulunmadığı saptandı.

🔖

Cite This Article

KARABULUT, B., ALKAN, B., ŞANLI, U. A., USLU, R., SEZGİN, V. C., GÖKER, E., ÖZDEMİR, N. (2022). Prognostic factors in breast cancer patients treated with adjuvant chemotherapy. Türk Hematoloji Onkoloji Dergisi, Cilt: 14 - Sayı: 3, 123–127. https://ajindex.com/articles/624751

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594, 1993
  2. American Cancer Society Cancer Facts and Figures 1999. Atlanta, GA, American Cancer Society, 1999
  3. Cancer Statistics Review: 1973-1994. NIH Pub. No. 97-2789. Bethesda, MD, National Cancer Institute, 1997
  4. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases Cancer 1;63(1):181-7, 1989
  5. Quiet CA, Ferguson DJ, Weichselbaum RR, et al: Natural history of node-negative breast cancer: A study of 826 patients with long-term follow-up. J Clin Oncol 13:1144-1151, 1995
  6. Rosen PP, Groshen S, Kinne DW, et al: Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 TIN0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 11:2090, 1993
  7. Clark GM, McGuire WL, Hubay CA, et al: Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med 309:1343, 1983
  8. Anderson ED, Forrest AP, Levack PA, et al: Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer. Br J Cancer 60:223-226, 1989
  9. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and sur vival with amplification of the HER-2/neu onco- gene. Science 235:177-182, 1987
  10. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvantt therapy in women with node-positive early breast cancer [comments] [published erratum appears in N Engl J Med 331:211, 1994]. N Engl J Med 330:1260, 1994
  11. Baselga J, Seidman AD, Rosen PP, et al: HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications. Oncolo gy 11:43, 1997
  12. Lane D, Benchimol S: p53: oncogene or anti- oncogene? Genes Dev 4:1, 1990
  13. Mowat M, Cheng A, Kimura N, et al: Rearrangements of the cellular p53 gene in ery- throleukaemic cells transformed by Friend virus. Nature 314:633, 1985
  14. Lane DP: p53, guardian of the genome. Nature 358:15, 1992
  15. Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular patho- genesis. Cancer Res 54:4855, 1994
  16. Lane D, Benchimol S: p53: oncogene or anti- oncogene? Genes Dev 4:1, 1990
  17. Montero S, Guzman C, Vargas C, Ballcstin C, Cortes-Funes H, Colomer R. Prognostic value of cytosolic p53 protein in breast cancer. Braz J Med Biol Res 2001 Jul;34(7